• aflatoxin B1;
  • allergy;
  • sensitization


  1. Top of page
  2. Hypothesis
  3. References

The worldwide increasing prevalence of allergic diseases over the last two decades, together with the fact that the prevalence of such diseases has become more notable in more developed than less developed countries, is a strong indication that environmental factors are of great significance in the development of allergic diseases. Some environmental factors (Endotoxins, BCG vaccination, Rubella and Hepatitis A infections, feeding with probiotics, etc.), as suggested in the hygiene hypothesis, may prevent the development of atopic diseases (1–5).

People, especially living in less developed countries, are frequently exposed to aflatoxins through food ingestion (6, 7). Aflatoxins are highly oxygenated, heterocyclic compounds produced by some strains of Aspergillus flavus and A. parasiticus. Four major structurally related aflatoxins have been identified which designated as B1, B2, G1 or G2. However, aflatoxin B1 (AFB1) is the primary form, and the majority of health effect studies have focused on it. Aspergillus species which produce aflatoxin B1 have a particular affinity for nuts, oilseeds and cereals (8, 9). Primarily, inadequate drying or improper storage of foods are certainly important in the occurrence of aflatoxins in the humidity of the tropics (9, 10). In contrast, in more developed countries, stringent sorting and clean up procedures are used to reduce aflatoxins to low levels in foods, but in spite of this, aflatoxin ingestion remains far too high, even in many developed countries, especially in rural areas (9, 11). In addition, aflatoxins are also found in significant amounts in respirable particles of grain dust and are an occupational health hazard when people are exposed to it (12–14). In utero exposure of AFB1 to both animals and humans has been reported and its exposure to developing individuals may take place through ingestion of mother's milk (14,15). The presence of AFB1 has also been reported in marketed milk samples from several countries (16). The contaminated milk is often consumed by growing individuals both in developed and developing countries. A growing individual exposed to AFB1 under such situations may be more susceptible to its toxicity compared with an adult. Aflatoxin B1 have been reported to impair the immune functions, including production of antibodies, cell-mediated responses and natural killer activity (17–19). It has been reported that AFB1 has a selective effect on cell-mediated immunity with a relatively minor effect on the humoral immune system (17). These reports indicate that the most probable mechanism of AFB1-induced cell-mediated immunosuppression is likely to be the inhibition of interleukin-2 (IL-2) and interferon-γ (IFN-γ) production (17, 20). Thus, the decrease of the IFN-γ level plays a major role in the development of allergen sensitization during infancy, while the capacity of T helper (Th) cells to secrete IFN-γ is markedly reduced in neonates (21–23). For this reason, we suggest that the reduced neonatal IFN-γ producing capacity would be even more pronounced in infants that were exposed to AFB1 especially during the infancy period and so there is a tendency to develop allergic sensitization. Moreover, it has been indicated that TNF-α and IL-1α, which play a role in the development of cell-mediated immunity by generating IL-2 and IL-12, are inhibited by AFB1 (18, 24). For instance, AFB1 can affect cell-mediated immunity by inhibiting these cytokines resulting in an inhibition of signals activating Th1 cells to respond to foreign antigens. Atopic diseases are developed as a result of the conversion of naive Th cells to Th2 instead of Th1 (21). When exposure to AFB1 occurs during the first years of life, inhibited Th1 immune response may stimulate the balance of Th1/Th2 skew toward Th2 immune response.

T helper 1 cells protect against asthma and allergy and can reverse the effects of Th2 driven inflammation. The beneficial role of the Th1 cells in allergic disease is supported by studies that CD8+ T cells secreting enhanced amounts of IFN-γ maintain homeostasis after allergen inhalation (25). Additionally, the level of IFN-γ appears to contribute to the severity of the disease (26).

In conclusion, this issue is one of the major health problems faced by people, especially those living in less developed countries. As AFB1 is excreted in both mother's milk and cow's milk, which are consumed widely by infants, it is a significant problem (14, 16). Because of their high toxicity, low limits for aflatoxins in foods and feeds have been set by many countries. According to recent agreements, 15 μg/kg of total AFB1 is likely to become the maximum level permitted in all world-traded food commodities (9).

It is noteworthy that in Africa, asthma is often seasonal and 90% of asthmatic patients were skin test positive to house dust mite (27, 28). We speculated that this may be the result of the ideal conditions for mite and also aspergillus molds growth during wet season in tropical countries when a high relative humidity occurs. In contrast, people who live in rural areas of Africa are more exposed to AFB1 and yet display a lower prevalence of atopic diseases when compared with western population. We thought that because of being immunosuppressive, a secondary AFB1 may increase bacterial, viral and parasitic infections, and subsequently Th1 immune response may be stimulated. Although we possess a reasonable knowledge, further study is necessary to understand the effects of aflatoxin on atopic diseases.


  1. Top of page
  2. Hypothesis
  3. References
  • 1
    Shaheen SO, Aaby P, Hall AJ et al. Measles and atopy an Guinea-Bissau. Lancet 1996;347: 17921796.
  • 2
    Matricardi PM, Rosmini F, Ferringo L, Nisini R, Rapicetta M, Chionne P. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. BMJ 1997;314: 9991003.
  • 3
    Shirakawa T, Enomoto T, Shimazu SI, Hopkins JM. The inverse association between tuberculin responses and atopic disorders. Science 1997;275: 7779.
  • 4
    Oyama N, Sudo N, Sogawa H, Kubo C. Antibiotic use during infancy promotes a shift in the TH1/TH2 balance toward TH2-dominant immunity in mice. J Allergy Clin Immunol 2001;107: 153159.
  • 5
    Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo controlled trial. Lancet 2001;357: 10761079.
  • 6
    ISAAC Steering Committee. Worldwide variations in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. ISAAC: Lancet 1998;351: 12251232.
  • 7
    WHO. Environmental health criteria II – mycotoxins. Geneva: World Health Organization, 1979.
  • 8
    Ciegler A, Bennett JW. Mycotoxins and mycotoxicoses. Bioscience 1980;30: 512515.
  • 9
    Pitt JI. Toxigenic fungi and mycotoxins. Br Med Bull 2000;56: 184192.
  • 10
    Cole RJ, Hill RA, Blakenship PD, Sanders RH, Garren H. Influence of irrigation and drought stress on invasion of Aspergillus flavus in corn kernels and peanut pods. Dev Ind Microbiol 1982;23: 299326.
  • 11
    Hendrickse RG, Maxwell SM, Young R. Aflatoxins and heroin. Toxicology 1989;296: 1257.
  • 12
    Sorenson WG, Jones W, Simpson J, Davidson JI. Aflatoxin inrespirable airborne peanut dust. J Toxicol Environ Health 1984;14: 525533.
  • 13
    Zennie TM. Identification of aflatoxin B1 in grain elevators dusts in central Illinois. J Toxicol Environ Health 1984;13: 589593.
  • 14
    Coulter JB, Lamplugh SM, Sulimen GI, Omer MIA, Hendrickse RG. Aflatoxins in human breast milk. Ann Trop Paed 1984;2: 6166.
  • 15
    Wild CP, Rasheed FN, Jawla MFB, Hall AJ, Jansen LAM, Montesano R. In-utero exposure to aflatoxin in West Africa. Lancet 1991;337: 1602.
  • 16
    VanEgmond HP, Paulsch WE. Mycotoxins in milk and milk products. Neth Milk Dairy J 1986;40: 175178.
  • 17
    Reddy RV, Sharma RA. Effects of aflatoxin B1 on murine lymphocyte functions. Toxicology 1989;54: 3144.
  • 18
    Dugyala RR, Sharma RP. The effect of aflatoxin B1 on cytokine mRNA and corresponding protein levels in peritoneal macrophages and splenic lymphocytes.. Int J Immunopharmac 1997;18: 599608.
  • 19
    Raisuddin S, Singh KP, Zaidi SIA, Paul BN, Ray PK. Immunosuppresive effects of aflatoxin in growing rats. Mycopatologia 1993;124: 189194.
  • 20
    Hatori Y, Sharma RP, Watten RP. Resistance of C57BL/6 mice to immunosuppresive effects of aflatoxin B1 and relationship with neuroendocrine mechanisms. Immunopharmacology 1991;22: 127136.
  • 21
    Tang ML, Kemp AS, Thorburn J, Hill DJ. Reduced interferon-gamma secretion in neonates and subsequent atopy. Lancet 1994;344: 983985.
  • 22
    Prescott SL, Macabuas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999;353: 196200.
  • 23
    Rinas U, Horneff G, Wahn U. Interferon-γ production by cord-blood mononuclear cells is reduced in newborns with a family history of atopic disease and is independent from cord blood IgE levels. Pediatr Allergy Immunol 1993;4: 6064.
  • 24
    Fiers W. Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285: 199212.
  • 25
    McMenamin C, Pimm C, McKersey M, Holt PG. Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells. Science 1994;165: 18691871.
  • 26
    Corrigan CJ, Kay AB. CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am Rev Respir Dis 1990;141: 970977.
  • 27
    Mohammed N, Ng'ang'a L, Odhihambo J, Nyamwaya J, Menzies R. Home environment and asthma in Kenyan school children: a case-controlled study. Thorax 1995;50: 7478.
  • 28
    Buchanan DJ, Jones IG. Mites and house dust mite allergy in bronchial asthma in Northern Zambia. Postgrad Med J 1974;50: 680682.